Research programme: hepatitis C virus NS5 protein inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: hepatitis C virus NS5 protein inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-929075

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Indoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 20 Jun 2016 No development reported - Preclinical for Hepatitis C in USA (PO)
  • 20 Jun 2013 Bristol-Myers Squibb withdraws a phase I trial in Hepatitis C (treatment-naive) prior to enrolment (NCT01525212)
  • 31 Jan 2012 Preclinical trials in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top